GlassScriptPhysician profile
Arie Rave
NPI 1184635377
$6,115.61
in general payments reported to CMS, 2019-2025
20 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $519 · 2021: $1,095 · 2022: $994 · 2023: $1,139 · 2024: $861 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,657.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.27 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,406.40 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $729.47 | 2022-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.41 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $441.54 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $305.92 | 2022-2025 | Airsupra, Farxiga |
| Braeburn INC. | $252.90 | 2024-2025 | Brixadi |
| Alkermes, INC. | $187.80 | 2019-2023 | Vivitrol |
| Orexo US, INC. | $108.34 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.33 | 2021 | |
| Allergan, INC. | $71.43 | 2019 | |
| Indivior INC. | $54.76 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $40.71 | 2022-2023 | Nuzyra |
| Inspire Medical Systems, INC. | $17.21 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $16.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $15.83 | 2021 | |
| Circassia INC. | $14.99 | 2019 | |
| Harmony Biosciences LLC | $14.78 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2019 | |
| Horizon Therapeutics Plc | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arie Rave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.